GENSIGHT BIOLOGICS SA (SIGHT.PA) Fundamental Analysis & Valuation

EPA:SIGHT • FR0013183985

Current stock price

0.082 EUR
0 (0%)
Last:

This SIGHT.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. SIGHT.PA Profitability Analysis

1.1 Basic Checks

  • In the past year SIGHT has reported negative net income.
  • SIGHT had a negative operating cash flow in the past year.
  • In the past 5 years SIGHT always reported negative net income.
  • SIGHT had a negative operating cash flow in each of the past 5 years.
SIGHT.PA Yearly Net Income VS EBIT VS OCF VS FCFSIGHT.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M

1.2 Ratios

  • SIGHT has a Return On Assets of -230.17%. This is amonst the worse of the industry: SIGHT underperforms 90.48% of its industry peers.
Industry RankSector Rank
ROA -230.17%
ROE N/A
ROIC N/A
ROA(3y)-187.69%
ROA(5y)-144.02%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SIGHT.PA Yearly ROA, ROE, ROICSIGHT.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100 -200

1.3 Margins

  • SIGHT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SIGHT.PA Yearly Profit, Operating, Gross MarginsSIGHT.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200K -400K -600K -800K -1M

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. SIGHT.PA Health Analysis

2.1 Basic Checks

  • SIGHT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • SIGHT has more shares outstanding than it did 1 year ago.
  • SIGHT has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, SIGHT has a worse debt to assets ratio.
SIGHT.PA Yearly Shares OutstandingSIGHT.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
SIGHT.PA Yearly Total Debt VS Total AssetsSIGHT.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -49.96, we must say that SIGHT is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of SIGHT (-49.96) is worse than 91.67% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -49.96
ROIC/WACCN/A
WACC6.23%
SIGHT.PA Yearly LT Debt VS Equity VS FCFSIGHT.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M

2.3 Liquidity

  • SIGHT has a Current Ratio of 0.39. This is a bad value and indicates that SIGHT is not financially healthy enough and could expect problems in meeting its short term obligations.
  • SIGHT has a worse Current ratio (0.39) than 90.48% of its industry peers.
  • A Quick Ratio of 0.39 indicates that SIGHT may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.39, SIGHT is doing worse than 89.29% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.39
Quick Ratio 0.39
SIGHT.PA Yearly Current Assets VS Current LiabilitesSIGHT.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. SIGHT.PA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 25.26% over the past year.
  • The Revenue for SIGHT has decreased by -114.53% in the past year. This is quite bad
  • SIGHT shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -81.32% yearly.
EPS 1Y (TTM)25.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.2%
Revenue 1Y (TTM)-114.53%
Revenue growth 3Y-92.71%
Revenue growth 5Y-81.32%
Sales Q2Q%-99.76%

3.2 Future

  • SIGHT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.95% yearly.
  • Based on estimates for the next years, SIGHT will show a very strong growth in Revenue. The Revenue will grow by 193.70% on average per year.
EPS Next Y-61.64%
EPS Next 2Y-19.93%
EPS Next 3Y13.95%
EPS Next 5YN/A
Revenue Next Year-16.67%
Revenue Next 2Y164.58%
Revenue Next 3Y193.7%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SIGHT.PA Yearly Revenue VS EstimatesSIGHT.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 20M 40M 60M
SIGHT.PA Yearly EPS VS EstimatesSIGHT.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

Find the best growth stocksShow best growing peers

0

4. SIGHT.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SIGHT. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SIGHT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SIGHT.PA Price Earnings VS Forward Price EarningsSIGHT.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SIGHT.PA Per share dataSIGHT.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.2 -0.4 -0.6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SIGHT's earnings are expected to grow with 13.95% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-19.93%
EPS Next 3Y13.95%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SIGHT.PA Dividend Analysis

5.1 Amount

  • SIGHT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SIGHT.PA Fundamentals: All Metrics, Ratios and Statistics

GENSIGHT BIOLOGICS SA

EPA:SIGHT (4/15/2026, 2:52:51 PM)

0.082

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-07
Earnings (Next)07-08
Inst Owners26.11%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap19.27M
Revenue(TTM)-218.00K
Net Income(TTM)-19.00M
Analysts80
Price Target0.31 (278.05%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-29.07%
PT rev (3m)-29.07%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)32.57%
EPS NY rev (3m)-4.12%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-16.67%
Revenue NY rev (3m)-45.26%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.11
EYN/A
EPS(NY)-0.61
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0
BVpS-0.11
TBVpS-0.11
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -230.17%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-187.69%
ROA(5y)-144.02%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover-0.03
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.39
Quick Ratio 0.39
Altman-Z -49.96
F-Score3
WACC6.23%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.2%
EPS Next Y-61.64%
EPS Next 2Y-19.93%
EPS Next 3Y13.95%
EPS Next 5YN/A
Revenue 1Y (TTM)-114.53%
Revenue growth 3Y-92.71%
Revenue growth 5Y-81.32%
Sales Q2Q%-99.76%
Revenue Next Year-16.67%
Revenue Next 2Y164.58%
Revenue Next 3Y193.7%
Revenue Next 5YN/A
EBIT growth 1Y-12.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-4.44%
EBIT Next 3Y33.06%
EBIT Next 5YN/A
FCF growth 1Y29.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.12%
OCF growth 3YN/A
OCF growth 5YN/A

GENSIGHT BIOLOGICS SA / SIGHT.PA Fundamental Analysis FAQ

What is the fundamental rating for SIGHT stock?

ChartMill assigns a fundamental rating of 1 / 10 to SIGHT.PA.


What is the valuation status of GENSIGHT BIOLOGICS SA (SIGHT.PA) stock?

ChartMill assigns a valuation rating of 0 / 10 to GENSIGHT BIOLOGICS SA (SIGHT.PA). This can be considered as Overvalued.


Can you provide the profitability details for GENSIGHT BIOLOGICS SA?

GENSIGHT BIOLOGICS SA (SIGHT.PA) has a profitability rating of 0 / 10.


What is the earnings growth outlook for GENSIGHT BIOLOGICS SA?

The Earnings per Share (EPS) of GENSIGHT BIOLOGICS SA (SIGHT.PA) is expected to decline by -61.64% in the next year.